SPRO vs. CRNC
SPRO (Spero Therapeutics, Inc.) and CRNC (Cerence Inc.) are both stocks. SPRO operates in Biotechnology (Healthcare), while CRNC operates in Software - Application (Technology). Over the past 5 years, SPRO returned -31.31%/yr vs -37.36%/yr for CRNC. At a 0.24 correlation, their price movements are largely independent.
Performance
SPRO vs. CRNC - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, SPRO achieves a -5.15% return, which is significantly lower than CRNC's -1.22% return.
SPRO
- 1D
- -3.07%
- 1M
- -19.93%
- YTD
- -5.15%
- 6M
- -6.75%
- 1Y
- -26.82%
- 3Y*
- 11.37%
- 5Y*
- -31.31%
- 10Y*
- —
CRNC
- 1D
- -1.95%
- 1M
- -3.83%
- YTD
- -1.22%
- 6M
- -7.21%
- 1Y
- 22.51%
- 3Y*
- -27.96%
- 5Y*
- -37.36%
- 10Y*
- —
SPRO vs. CRNC - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
SPRO Spero Therapeutics, Inc. | -5.15% | 126.21% | -29.93% | -15.03% | -89.19% | -17.43% | 101.66% | -9.04% |
CRNC Cerence Inc. | -1.22% | 36.18% | -60.07% | 6.10% | -75.82% | -23.73% | 344.01% | 31.65% |
Correlation
The correlation between SPRO and CRNC is 0.22, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.22 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.20 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.22 |
Correlation (All Time) Calculated using the full available price history since Oct 2, 2019 | 0.24 |
Fundamentals
SPRO:
$126.59M
CRNC:
$495.25M
SPRO:
$0.39
CRNC:
-$0.44
SPRO:
2.31
CRNC:
1.56
SPRO:
2.39
CRNC:
3.12
SPRO:
$54.77M
CRNC:
$302.14M
SPRO:
$54.51M
CRNC:
$235.95M
SPRO:
$12.49M
CRNC:
$34.08M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
SPRO vs. CRNC — Risk / Return Rank
SPRO
CRNC
SPRO vs. CRNC - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Spero Therapeutics, Inc. (SPRO) and Cerence Inc. (CRNC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| SPRO | CRNC | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.72 | ||
| Sortino ratioReturn per unit of downside risk | -1.35 | ||
| Omega ratioGain probability vs. loss probability | 0.96 | 1.13 | -0.17 |
| Calmar ratioReturn relative to maximum drawdown | -0.68 | 0.40 | -1.08 |
| Martin ratioReturn relative to average drawdown | -1.16 | 0.83 | -2.00 |
Loading charts...
Drawdowns
SPRO vs. CRNC - Drawdown Comparison
The maximum SPRO drawdown since its inception was -97.46%, roughly equal to the maximum CRNC drawdown of -98.22%. Use the drawdown chart below to compare losses from any high point for SPRO and CRNC.
Loading charts...
Drawdown Indicators
| SPRO | CRNC | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.46% | -98.22% | +0.76% |
Max Drawdown (1Y)Largest decline over 1 year | -39.80% | -55.92% | +16.12% |
Max Drawdown (3Y)Largest decline over 3 years | -68.89% | -91.96% | +23.07% |
Max Drawdown (5Y)Largest decline over 5 years | -97.13% | -98.09% | +0.96% |
Current DrawdownCurrent decline from peak | -89.99% | -92.09% | +2.10% |
Average DrawdownAverage peak-to-trough decline | -62.42% | -63.22% | +0.80% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 23.07% | 27.05% | -3.98% |
Volatility
SPRO vs. CRNC - Volatility Comparison
Spero Therapeutics, Inc. (SPRO) has a higher volatility of 33.20% compared to Cerence Inc. (CRNC) at 29.68%. This indicates that SPRO's price experiences larger fluctuations and is considered to be riskier than CRNC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| SPRO | CRNC | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 33.20% | 29.68% | +3.52% |
Volatility (6M)Calculated over the trailing 6-month period | 45.15% | 59.27% | -14.12% |
Volatility (1Y)Calculated over the trailing 1-year period | 58.66% | 87.66% | -29.00% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 152.13% | 113.90% | +38.23% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 124.91% | 106.42% | +18.49% |
Dividends
SPRO vs. CRNC - Dividend Comparison
Neither SPRO nor CRNC has paid dividends to shareholders.
Financials
SPRO vs. CRNC - Financials Comparison
This section allows you to compare key financial metrics between Spero Therapeutics, Inc. and Cerence Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
SPRO and CRNC have a correlation of 0.22, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
SPRO has higher volatility (33.20%) compared to CRNC (29.68%). In terms of maximum drawdown, SPRO dropped -97.46% vs CRNC's -98.22%.
CRNC currently has the higher Sharpe Ratio (0.26 vs -0.46), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for SPRO and CRNC
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer